GS030
Asset
Optogenetic gene therapy encoding a channelrhodopsin to restore light sensitivity in retinal ganglion cells
- Stage
- Phase 1
- Modality
- Gene therapy
- Target
- Not known
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Retinitis pigmentosa
Phase 1, businesswire.com, 8 Oct 2026
In the full profile
- Owner and partners2
- Competitors1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.